New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine

The U.S. Food and Drug Administration has approved Moderna's new mRNA-based influenza vaccine, named mFlusiva, marking the first time this technology—which was central to ending the COVID-19 pandemic—has been applied to a flu shot. Announced by the manufacturer, the vaccine is specifically intended for adults aged 50 and older.

The approval represents a significant shift in vaccine development, introducing messenger RNA technology to seasonal influenza prevention. The initiative aims to provide older populations with an updated immunization option utilizing the platform proven during the global pandemic.